Group 1 - The core viewpoint of the article highlights the recent stock performance of WuXi Biologics, which experienced a decline of 2.01% on August 6, trading at 31.22 HKD per share with a transaction volume of 4.38 billion HKD [1] - WuXi Biologics is recognized as a leading global provider of biologics services, offering comprehensive, integrated, and highly customized services throughout the entire process from discovery and development to production of biologics [1] - As of 2016, the company held a significant 48% market share in China's biologics R&D market and has established partnerships with 12 out of the top 20 global pharmaceutical companies [1] Group 2 - For the fiscal year ending 2024, WuXi Biologics reported total revenue of 18.675 billion HKD and a net profit of 3.356 billion HKD [1] - The company is set to disclose its interim report for the fiscal year 2025 on August 19 [1]
药明生物(02269)下跌2.01%，报31.22元/股